AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 111 min read$TENX

ING Groep reports zero stake in Tenax Therapeutics (TENX)

ING Groep N.V. and ING Capital Markets LLC filed an amended Schedule 13G/A, disclosing zero ownership in Tenax Therapeutics (TENX) as of September 11, 2026. The filing indicates no voting or dispositive power over Tenax's common stock, with 37,423,917 shares outstanding as of July 28, 2026.

Original reporting
stocktitan.net
Published Sep 11, 2026, 5:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 11:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TENX
Bearish
medium confidence
Mentioned
$TENX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TENXBearishLow
01

Why it matters

The filing removes a known institutional holder from TENX's shareholder base, which may affect liquidity and perception.

02

Market read

A routine ownership filing with modest relevance for TENX traders; unlikely to drive major market moves.

03

What to watch

Potential hidden strategic partnership or upcoming financing that prompted ING to exit.

Relevance 4/10Novelty 3/10Timing: as of September 11, 2026

Background

ING Groep N.V. and its capital markets arm filed an amended Schedule 13G/A indicating zero beneficial ownership of TENX shares.

Company-level read

Ticker impact

$TENXBearishMedium confidence
Context

ING Groep filed a Schedule 13G/A showing it no longer holds any shares of Tenax Therapeutics (TENX).

Expected impact

potential short-term downside of 2‑4% as the market absorbs the reduced ownership.

Evidence & confidence

Stake reductions by major investors often signal reduced confidence; however, the filing provides no further context, so impact is limited.

Market effects

Sector

Minor signal for the biotech sector; no broader sector impact.

Regional

Limited to U.S. biotech investors.

Global

Low

Counterpoint

What could challenge this read

The stake cut could be a portfolio rebalancing unrelated to TENX fundamentals, so price may remain stable.

Key entities

  • Institutional Investor
    ING Groep N.V.

    European banking group that previously held TENX shares.

  • Company
    Tenax Therapeutics, Inc.

    U.S. biotech company listed under ticker TENX.

Read at source← All news

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min
AUG 11
$TENXHighAI 9/10

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF

Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.

thepharmaletter.com2 min